November 1987
Volume 28, Issue 11
Free
Articles  |   November 1987
Suicide enzyme inhibition as a chemotherapeutic strategy for controlling metastases derived from intraocular melanomas.
Author Affiliations
  • J Y Niederkorn
    Department of Ophthalmology, University of Texas Health Science Center, Dallas 75235-9057.
  • G E Sanborn
    Department of Ophthalmology, University of Texas Health Science Center, Dallas 75235-9057.
  • J W Gamel
    Department of Ophthalmology, University of Texas Health Science Center, Dallas 75235-9057.
Investigative Ophthalmology & Visual Science November 1987, Vol.28, 1844-1850. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J Y Niederkorn, G E Sanborn, J W Gamel; Suicide enzyme inhibition as a chemotherapeutic strategy for controlling metastases derived from intraocular melanomas.. Invest. Ophthalmol. Vis. Sci. 1987;28(11):1844-1850.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

The anti-metastatic effect of two chemotherapeutic agents was analyzed in a murine melanoma model. Difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, was administered as a 2% aqueous solution in the drinking water. A second drug, dacarbazine (DTIC) was administered intravenously in single bolus injections. Each drug produced significant anti-metastatic effects that were manifested by a reduction in the number of pulmonary metastases and in the prolongation of host survival times. Maximal chemotherapy was achieved when both drugs were combined. The specificity, low toxicity, ease of administration, infrequent side effects, and therapeutic effectiveness of DFMO make it an attractive candidate for clinical use in human subjects being treated for uveal melanoma. The effectiveness of DTIC against blood-borne melanoma cells suggests that this drug may prove useful as a prophylactic adjunct in patients undergoing enucleation of a melanoma-containing eye.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×